Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

IntelGenx first CDMO packaging accord to generate $9-million in revenue over 3 years

IntelGenx (TSX:IGX; OTCQB:IGXT) expects to generate $9-million in revenue over three years from an agreement for packaging a pharmaceutical oral film product that an undisclosed contract development and manufacturing...

August 11, 2023

Markets

Ladenburg cuts Salarius to neutral; removes PT

Ladenburg Thalmann downgraded Salarius Pharmaceuticals (NASDAQ:SLRX) to “neutral” from “buy” and removed its price target after the company disclosed it is exploring strategic alternatives and implement cost-cutting...

August 11, 2023

Developments

Inversago Pharma accepts $1.1-billion offer from Novo Nordisk

Closely-held Inversago Pharma of Montreal agreed to be acquired by Denmark’s Novo Nordisk for up to $1.1-billion (U.S.) in cash if certain development and commercial milestones are achieved. Inversago Pharma is a...

August 10, 2023

Developments

Absci, Caltech receive Gates grant to develop affordable HIV vaccines

Absci (NASDAQ:ABSI) and leading researchers at the California Institute of Technology received a grant from the Bill & Melinda Gates Foundation for a joint effort to discover affordable HIV therapeutic vaccinations...

August 10, 2023

Developments

Palisade Bio flunks Phase 2 study in post-surgical abdominal adhesions

Palisade Bio’s (NASDAQ:PALI) U.S. Phase 2 PROFILE study evaluating LB1148 for reduction in intra-abdominal adhesions in subjects following elective bowel resection did not achieve its primary endpoint. Of the patients...

August 9, 2023

Developments

Precigen Phase 1/2 AdenoVerse study confirmed as pivotal

The FDA has agreed that the ongoing Phase 1/2 single-arm study of Precigen’s (NASDAQ:PGEN) investigational PRGN-2012 AdenoVerse immunotherapy for the treatment of recurrent respiratory papillomatosis will serve as...

August 9, 2023

Markets

Leerink ups Quanterix to OP; PT to $30

Leerink Partners upgraded Quanterix (NASDAQ:QTRX) to “outperform” from “market perform” and raised its price target to $30 from $25, citing strong evidence for its assays redevelopment effort. Analyst Puneet Souda...

August 8, 2023

Developments

Anixa opens enrollment for Keytruda arm in breast cancer vaccine trial

Anixa Biosciences’ (NASDAQ:ANIX) partner, Cleveland Clinic, has begun enrolling subjects in a treatment arm evaluating the combination of the company’s breast cancer vaccine with Keytruda. The treatment arm is an...

August 7, 2023

Developments

Vistagen posts positive Phase 3 results for nasal spray in social anxiety disorder

Vistagen (NASDAQ:VTGN) announced positive top-line results from its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol nasal spray in adults diagnosed with social anxiety disorder...

August 7, 2023

Developments

LENZ partner cleared for Phase 3 presbyopia trial in China

LENZ Therapeutics’ China partner, Ji Xing Pharmaceuticals, was cleared by the Center for Drug Evaluation of the National Medical Products Administration of the PRC to conduct a Phase 3 clinical trial of LNZ100...

August 7, 2023

Developments

Mesoblast receives FDA complete response for BLA in GvHD

Mesoblast (NASDAQ:MESO, ASX:MSB) received a complete response letter to its biologics license application resubmission for remestemcel-L for the treatment of pediatric steroid-refractory acute graft versus host disease...

August 4, 2023

Developments

Femasys begins pivotal trial of non-surgical permanent birth control candidate

Femasys (NASDAQ:FEMY) initiated enrollment in a prospective multi-center pivotal trial to investigate the safety and efficacy of its investigational permanent birth control candidate, FemBloc. The trial is designed to...

August 3, 2023

IntelGenx first CDMO packaging accord to generate $9-million in revenue over 3 years

Ladenburg cuts Salarius to neutral; removes PT

Inversago Pharma accepts $1.1-billion offer from Novo Nordisk

Absci, Caltech receive Gates grant to develop affordable HIV vaccines

Palisade Bio flunks Phase 2 study in post-surgical abdominal adhesions

Precigen Phase 1/2 AdenoVerse study confirmed as pivotal

Leerink ups Quanterix to OP; PT to $30

Anixa opens enrollment for Keytruda arm in breast cancer vaccine trial

Vistagen posts positive Phase 3 results for nasal spray in social anxiety disorder

LENZ partner cleared for Phase 3 presbyopia trial in China

Mesoblast receives FDA complete response for BLA in GvHD

Femasys begins pivotal trial of non-surgical permanent birth control candidate

General

More